CD274 and neoplasm: At present, the standard biomarkers for clinicians to select patients who are eligible for immunotherapy are immunohistochemistry assays for PD-L1 protein and tumour mutation burden (TMB), but some studies have found conflicting results when using the two biomarkers to predict immunotherapy response or overall survival.